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Abstract
Numerous studies have described structural and functional
abnormalities of the thalamus in schizophrenia, but surpris-
ingly few studies have examined neurochemical abnormalities
that accompany these pathological changes. We previously
identified abnormalities of multiple molecules associated with
glutamatergic neurotransmission, including changes in NMDA
receptor subunit transcripts and binding sites and NMDA
receptor-associated post-synaptic density (PSD) protein
transcripts in the thalamus of elderly patients with schizo-
phrenia. In the present study, we performed western blot
analysis to determine whether protein levels of NMDA
receptor subunits (NR1, NR2A, NR2B) and associated PSD
proteins (NF-L, PSD95, SAP102) are altered in schizophrenia.
Thalamic tissue from each subject was grossly dissected into
two regions: a dorsomedial region containing limbic-associ-
ated dorsomedial, anterior and central medial thalamic nuclei;
and a ventral thalamus region that primarily consisted of the
ventral lateral nucleus. We observed increased protein
expression of the NR2B NMDA receptor subunit and its
associated intracellular protein, PSD95, in the dorsomedial
thalamus of patients with schizophrenia, but the other mole-
cules were unchanged, and we found no changes in the
ventral thalamus. These data provide additional evidence of
thalamic neurochemical abnormalities, particularly in thalamic
nuclei which project to limbic regions of the brain. Further,
these findings provide additional evidence of NMDA receptor
alterations in schizophrenia, which may play an important role
in the neurobiology of the illness.
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The thalamus contains numerous topographically organized
nuclei that transmit sensory and higher order inputs to and
from cortical and limbic structures (Jones 1998). Through
these connections, the thalamus plays a critical role in
regulating sensory processing, attention and other executive
functions commonly disturbed in schizophrenia. Numerous
in vivo imaging studies have identified thalamic abnormalities
in schizophrenia. These include reports of reduced thalamic
volume (Andreasen et al. 1990, 1994; Flaum et al. 1995;
Buchsbaum and Hazlett 1998; Gur et al. 1998; Staal et al.
1998; Dasari et al. 1999; Ettinger et al. 2001; Gilbert et al.
2001; Konick and Friedman 2001), reduced thalamic meta-
bolism (Resnick et al. 1988; Tamminga et al. 1992;
Silbersweig et al. 1995; Vita et al. 1995; Andreasen et al.
1996; Buchsbaum et al. 1996; Heckers et al. 1998; Hazlett
et al. 1999), and sensory processing deficits in patients
with schizophrenia that, at least partly, involve thalamic
hypofunction (Braus et al. 2002; Takahashi et al. 2004;
Butler et al. 2005; Kiehl et al. 2005; Symond et al. 2005).
Many post-mortem stereological studies have found
decreased cell numbers in the mediodorsal nucleus of the
thalamus (Pakkenberg 1990, 1992, 1993; Danos et al. 1998,
2002, 2003; Popken et al. 2000; Young et al. 2000; Byne
et al. 2002), although two recent studies were unable to
replicate these findings (Cullen et al. 2003; Dorph-Petersen
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et al. 2004). Considering the wealth of evidence for structural
pathology and thalamic dysfunction in schizophrenia, we
conducted a series of studies to examine possible neuro-
chemical substrates that may be associated with thalamic
abnormalities in the illness. Much of this work has focused on
glutamatergic abnormalities in the thalamus (for review see
Clinton and Meador-Woodruff 2004a), partly because glu-
tamate is a predominant neurotransmitter used in the thalamus
and because glutamatergic dysfunction has been hypothesized
to be involved in schizophrenia (Goff and Coyle 2001).
The strongest evidence for glutamate dysfunction in
schizophrenia is the finding that psychotomimetic agents
like phencyclidine and ketamine, which block the NMDA
glutamate receptor channel, can trigger a schizophrenia-like
syndrome in healthy subjects (Domino and Luby 1981) and
exacerbate symptoms in patients with schizophrenia (Lahti
et al. 1995). Clinical data show that NMDA receptor glycine
site agonists (e.g. glycine, D-cycloserine and D-serine), which
positively modulate NMDA channel function, significantly
improve cognitive deficits and negative symptoms when
given in combination with anti-psychotics (Javitt et al. 1994;
Goff et al. 1995; Tsai et al. 1998). Finally, post-mortem
studies have revealed NMDA receptor abnormalities in
limbic structures implicated in schizophrenia, including the
prefrontal cortex (Dracheva et al. 2001; Toyooka et al. 2002;
Emamian et al. 2004; Mueller and Meador-Woodruff 2004),
temporal cortex (Grimwood et al. 1999; Nudmamud-Thanoi
and Reynolds 2004), hippocampus (Dean et al. 1999; Gao
et al. 2000; Toro and Deakin 2005), substantia nigra
(Mueller et al. 2004) and thalamus (Ibrahim et al. 2000;
Clinton et al. 2003; Clinton and Meador-Woodruff 2004b).
Taken together, these data suggest that hypoglutamatergic
neurotransmission plays a role in the pathophysiology of
schizophrenia, and that boosting NMDA receptor transmis-
sion through various mechanisms may be a promising
approach for pharmacotherapy of the illness (Javitt 2004).
Glutamate neurotransmission involves several classes of
molecules, including pre- and post-synaptic glutamate
receptors and receptor-associated intracellular proteins. The
NMDA glutamate receptor consists of several subunits,
including the obligate NR1 subunit, and combinations of
NR2 subunits A–D (Hollmann and Heinemann 1994).
NMDA receptors also interact with intracellular proteins
enriched in the post-synaptic density (PSD), which link the
receptor to the cytoskeleton, kinases, phosphatases, and other
signal transduction or receptor trafficking pathways (Sheng
and Pak 2000). Considering the complexity of the glutamate
system, it is possible that glutamate dysfunction in schizo-
phrenia may involve abnormalities of the NMDA receptor as
well as a disruption of other molecules involved in glutamate
neurotransmission. Glutamatergic abnormalities that are
hypothesized to be present in schizophrenia could be
explained by many single, or combinations of, alternative
possibilities, including altered release of glutamate, abnormal
expression of NMDA receptor subunits, or reduced capacity
of NMDA receptors to activate intracellular signal transduc-
tion pathways (Krystal et al. 1999).
Several studies from our laboratory have revealed altera-
tions in the expression of glutamate receptors and other
molecules involved in glutamatergic neurotransmission in the
thalamus of elderly patients with schizophrenia (Ibrahim
et al. 2000; Richardson-Burns et al. 2000; Smith et al.
2001a,b; Clinton et al. 2003, 2004). We initially found
reduced NMDA receptor subunit transcripts NR1 and NR2C,
and decreased polyamine and glycine binding sites of the
NMDA receptor complex in limbic thalamic nuclei in
schizophrenia, but we did not find prominent changes in
the expression of AMPA, kainate or metabotropic receptors
(Ibrahim et al. 2000; Richardson-Burns et al. 2000). Subse-
quent studies revealed altered transcript expression of a set of
NMDA receptor-associated intracellular molecules, inclu-
ding post-synaptic density protein 95 (PSD95), synapse-
associated protein 102 (SAP102), and neurofilament subunits
NF-L and NF-M (Clinton et al. 2003, 2004), suggesting that
glutamate dysfunction in this illness may not only involve
alterations in glutamate receptors themselves, but also
changes in intracellular molecules critical for glutamate
receptor-associated signal transduction. Finally, although
much of our work has focused on post-synaptic glutamate
receptors and associated molecules, we have also identified
abnormalities of pre-synaptic and glial-associated molecules
that participate in glutamate neurotransmission (Smith et al.
2001a,b). We reported increased expression of transcripts for
one of the vesicular glutamate transporters (VGLUT2) in
schizophrenia, which may reflect an increase of glutamate
release in brain regions that receive thalamic efferent
projections, such as the prefrontal cortex (Smith et al.
2001a). The expression of glial-localized Excitatory Amino
Acid Transporter (EAAT1) and EAAT2 transcripts was also
increased, but the neuronally-expressed EAAT3 and EAAT4
transcripts were unchanged in the thalamus in schizophrenia
compared with controls (Smith et al. 2001b).
Taken together, this series of in situ hybridization studies
suggests a significant dysregulation of glutamate neurotrans-
mission in the thalamus in schizophrenia. In the present
study, using tissue from the same collection of elderly
subjects as used in our earlier work, we have performed
western blot analysis to determine whether protein expres-
sion of the NMDA subunits and associated PSD molecules is
also altered in schizophrenia, and whether the pattern of
changes parallels those observed for mRNA expression.
Material and methods
Brain tissue preparation
Fifteen elderly patients with schizophrenia and eight non-psychiat-
rically ill individuals from the Mount Sinai Medical Center Brain
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Bank were studied (Table 1). Next of kin consent was obtained for
each subject. Neither age (t ¼ 1.65; d.f. ¼ 21; p ¼ 0.11), nor post-
mortem interval (t ¼ ) 1.74; d.f. ¼ 21; p ¼ 0.10) nor tissue pH
(t ¼ ) 1.25; d.f. ¼ 21; p ¼ 0.23) were significantly different
between diagnostic groups, although there was a trend for
differences in sex distribution (v2 ¼ 3.63; p ¼ 0.06). Each patient
and comparison brain underwent neuropathological examination,
and Alzheimer’s disease and other discernable neuropathological
conditions was specifically ruled out in each case. Brains were
prepared by slicing the left hemisphere into 0.8–1 cm coronal slabs,
which were snap frozen. Blocks containing thalamus were initially
cryostat-sectioned for in situ hybridization studies, and remaining
tissue blocks (approximately 3–4 mm thick) were grossly dissected
into dorsomedial and ventral thalamic areas (Fig. 1a). These regions
were identified for each subject primarily using the descriptions of
thalamic architecture of Jones (Steriade et al. 1997), and supple-
mented by a set of detailed atlases (Hirai and Jones 1989; Mai et al.
1997). The dorsomedial dissected region contained portions of the
dorsomedial nucleus and, in some cases, the anterior nucleus and
central medial nucleus of the thalamus. The dissected ventral region
contained portions of the ventral anterior and ventral lateral nuclei of
the thalamus.
Frozen dorsomedial and ventral thalamic samples (0.1–0.5 g of
tissue) from each patient were homogenized in 10 volumes of ice-
cold buffer containing 250 mM sucrose, 10 mM sodium phosphate,
1 mM EDTA and a cocktail of protease inhibitors (which included a
broad spectrum of serine, cysteine and metalloproteases, as well as
calpains; Roche, Indianapolis, IN, USA), with a pH of 7.4. Protein
concentrations were determined using a bicinchoninic acid (BCA)
protein assay kit (Pierce Chemical, Rockland, MA, USA).
Western blot analysis
Dorsomedial and ventral thalamus tissue homogenates (40 lg per
lane) from each patient were denatured in sample loading buffer
[10% glycerol, 2% sodium dodecyl sulfate (SDS), 5% 2-b-
mercaptoethanol, 63 mM Tris (pH 6.8) and 0.01% bromophenol
blue] at 95C for 4 min. Tissue samples, a pre-stained molecular
weight marker (Bio-Rad Laboratories, Hercules, CA, USA) and an
internal control of standard human thalamus homogenate were
loaded onto 1.0 mm thick 7.5% polyacrylamide gels and run for
45 min at 100 V using a Mini-PROTEAN II System (Bio-Rad
Laboratories, Hercules, CA, USA). As a single gel could not
accommodate all of the samples run in duplicate, protein samples
from patients with schizophrenia and control subjects were
alternately allocated on two polyacrylamide gels, together with the
molecular marker and internal positive control. Separated proteins
were transferred to nitrocellulose membranes (Bio-Rad), overnight
at 11 V, using a Trans-Blot Electrophoretic Transfer Cell (Bio-Rad)
with transfer buffer (25 mM Tris, 192 mM glycine).
Following the transfer procedure, blots were rinsed in high purity
water (15 min) and cut into sections containing the proteins of
interest. As there was sufficient separation between some of the
protein bands of interest, we were able to obtain data on multiple
proteins from each set of gels. For instance, one set of membranes
Table 1 Subject characteristics
Sex Age PMI (min) pH Cause of death
Control subjects (n ¼ 8) F 78 545 6.6 Cardiopulmonary failure
M 96 195 6.7 Cardiopulmonary failure
F 74 180 6.0 Cardiopulmonary failure
F 82 340 6.1 Cardiopulmonary arrest
F 64 1145 6.1 Pulmonary edema
M 93 1140 6.4 Congestive heart failure
F 73 203 6.3 Acute myocardial infarction
F 79 460 6.5 Acute myocardial infarction
Schizophrenia patients (n ¼ 15) M 52 1270 6.3 Cardiopulmonary failure
M 58 800 6.9 Cardiopulmonary failure
M 57 820 6.1 Cardiopulmonary arrest
M 69 820 6.2 Cardiopulmonary failure
F 83 1225 7.1 Cardiopulmonary arrest,
pancreatic cancer
F 85 320 6.3 Cardiopulmonary arrest
M 73 475 6.5 Cardiopulmonary failure
M 66 725 6.5 Acute cardiac failure
M 76 1270 6.1 Cardiogenic shock
F 97 555 6.5 Cardiopulmonary arrest
M 59 381 6.2 Pancreatitis
M 66 504 6.7 Cardiopulmonary arrest
F 82 1126 6.6 Cardiopulmonary arrest
F 79 595 6.8 Cardiac arrest
M 68 1036 6.6 Cardiopulmonary arrest
Control 2M : 6F 79.9 (64–96) 526 (180–1145) 6.3 (6.0–6.7)
Schizophrenia 10M : 5F 71.3 (52–97) 795 (320–1170) 6.5 (6.1–7.1)
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was cut into three portions: the top membrane strip contained the
band for 180 kDa NR2B, the middle strip contained the band for
100 kDa NR1 and the bottom strip contained the band for 50 kDa
b-tubulin. Three sets of gels were needed to obtain data for all of the
NMDA receptor subunits and post-synaptic proteins, and b-tubulin
expression was assessed in all gel sets to ensure consistency across
the experiments. Membranes were pre-incubated for 20–30 min at
room temperature (37C) in a blocking solution consisting of either
0.1 M phosphate-buffered saline (PBS) or 0.1 M Tris-buffered saline
(TBS) (both pH 7.6), 2–5% fat-free dry milk (Carnation, Wilkes-
Barre, PA, USA) depending on the antibody and, in some cases,
0.05% Tween-20. Table 2 describes the primary antibodies used in
this study, including information regarding the specific blocking
solutions and antibody concentrations, which were optimized for
each antibody. Membranes were incubated with primary antibodies
for the NMDA receptor subunits, associated PSD proteins or
b-tubulin in blocking solution overnight at 4C. Approximately 18 h
later, membranes were rinsed twice in distilled water, then incubated
for 2 h at room temperature (37C) with horseradish peroxidase-
conjugated goat anti-rabbit or anti-mouse secondary antibodies
(1 lg/mL; Sigma-Aldrich Corp., St Louis, MO, USA) in the
blocking solution indicated in Table 2. Following the 2 h incubation
with secondary antibody, membranes were rinsed twice (15 min) in
either PBS or TBS (according to the type of blocking solution used),
rinsed in either PBS or TBS with 0.05% Tween-20 for 5 min, and
finally washed 3–4 times (1 min) with distilled water. Immunolabe-
ling was visualized using an electrochemiluminescence (ECL)
western blotting analysis system (Amersham Biosciences, Piscata-
way, NJ, USA). ECL-treated membranes were placed between two
plastic transparencies, then apposed to ECL-Hyperfilm (Amersham
Biosciences) for 2–30 min.
Image and data analysis
Densitometry quantification of the band intensities was performed
within the range of linear exposure of the film using SCION IMAGE
BETA 3B for PC (Scion Corp., Frederick, MD, USA). Duplicate
samples were averaged for each subject. All of the blotting was
repeated, and differences in either NMDA receptor subunits or
PSD proteins were confirmed by an independent set of immuno-
blotting. In order to control for equal loading, we calculated ratios
of the optical density for the antibody of interest to the optical
density of the antibody directed against b-tubulin for each patient.
Statistical analysis was accomplished with 2-way ANOVA (diagno-
sis · thalamic subregion), followed by Fisher’s post-hoc compar-
isons. The Shapiro–Wilks’ W-test was used to ensure normality of























(b) β-tubulin, 50 kDa
Fig. 1 (a) Thalamic tissue blocks containing thalamus were initially
sectioned for in situ hybridization, then later dissected for western blot
analysis. The top left panel shows a representative section processed
for in situ hybridization for neurofilament-light (NF-L) mRNA. The top
right panel is a schematic diagram of the section, identifying major
nuclei present in this section: anterior nucleus, dorsomedial nucleus,
ventral thalamus (which includes the ventral anterior, ventral lateral
anterior and posterior nuclei) and the reticular nucleus. Thalamic tis-
sue blocks for each subject were dissected into a dorsomedial and
ventral portion, outlined by the dashed line in the schematic. Tissue
was then weighed, homogenized and prepared for western blot ana-
lysis. (b) Representative immunoblots for b-tubulin using dorsomedial
and ventral thalamus samples from a patient with schizophrenia (scz)
and a control subject (con); lanes show side-by-side duplicates of each
subject. (c) Scatterplots represent b-tubulin protein expression levels
in the dorsomedial and ventral thalamus in patients with schizophrenia
and comparison subjects. b-tubulin protein levels in dorsomedial and
ventral thalamus tissue were unchanged between diagnostic groups.
Table 2 Immunoblot conditions
Protein Origin Corresponding amino acids Length of peptide Blocking solution Dilution Company
NR1 Rat 917–938 21 5% TBST-milk 1 lg/mL Upstate Biotechnology
NR2A Mouse 1241–1441 200 3% PBS-milk 3 lg/mL Upstate Biotechnology
NR2B Mouse 1437–1456 19 2% PBS-milk 2 lg/mL Upstate Biotechnology
NF-L Human n.a. n.a. 3% TBST-milk 0.5 lg/mL Zymed Laboratories, Inc.
PSD-95 Human 77–299 223 3% PBS-milk 0.05 lg/mL Upstate Biotechnology
SAP102 Human 93–190 97 3% TBST-milk 10 lg/mL Chemicon International
b-tubulin Bovine 412–430 18 3% PBS-milk 0.5 lg/mL Upstate Biotechnology
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determine any possible relationships between continuously distri-
buted variables. Data were analyzed using SPSS 13.0 for
Windows, and for all tests a¼ 0.05.
Results
b-tubulin protein expression
We measured the expression of b-tubulin protein in all
samples to use as an internal control. The b-tubulin antibody
detected a single prominent band at 50 kDa (Fig. 1b). As all of
the other proteins of interest run well above this molecular
weight, each experimental blot was cut so that the top pieces
could be processed to detect the NMDA receptor subunits or
associated PSD proteins, and the bottom piece was processed
to assess b-tubulin in parallel for each subject. Data for
NMDA receptor subunits and associated PSD proteins are
presented as a ratio of the optical density value for the protein
band of interest over the optical density of the b-tubulin band
in the same lane. Similar levels of b-tubulin protein were
expressed in dorsomedial and ventral thalamus samples both
from patients with schizophrenia and control subjects
(Fig. 1c). There was no main effect for diagnosis (F ¼ 0.22;
d.f. ¼ 1,46; p ¼ 0.64) and region (F ¼ 0.34; d.f. ¼ 1,46;
p ¼ 0.56), and no diagnosis · region interaction (F ¼ 2.60;
d.f. ¼ 1,46; p ¼ 0.11). There were no correlations between
b-tubulin levels and age, tissue pH or post-mortem interval.
NMDA receptor subunit protein expression in
dorsomedial and ventral thalamus
Antibodies directed against the NMDA receptor subunits
NR1, NR2A and NR2B all detected single prominent bands
at the appropriate molecular weights (180 kDa for NR2B,
165 kDa for NR2A and 120 kDa for NR1; Fig. 2a). There
was no main effect of diagnosis (F ¼ 1.82; d.f. ¼ 1,46; p ¼
0.18) or region (F ¼ 1.37; d.f. ¼ 1,46; p ¼ 0.25) on NR2B
protein levels, but there was a significant diagnosis · tha-
lamic sub-region interaction (F ¼ 6.71; d.f. ¼ 1,46;
p < 0.05) (Fig. 2b). Post-hoc analysis revealed significantly
increased levels of NR2B protein in the subjects with
schizophrenia relative to comparison subjects in the dorso-
medial thalamus (p < 0.05; Fisher’s PLSD), while NR2B
expression in ventral thalamus was unchanged (Fig. 2b).
NR1 and NR2A protein expression was not different between
groups in either dorsomedial or ventral thalamus (Fig. 2b).
There was no main effect of diagnosis (F ¼ 1.52; d.f. ¼
1,46; p ¼ 0.22) or region (F ¼ 0.48; d.f. ¼ 1,46; p ¼ 0.49)
on NR1 protein levels and similarly, no main effect of
diagnosis (F ¼ 1.40; d.f. ¼ 1,46; p ¼ 0.24) or region (F ¼
0.45; d.f. ¼ 1,46; p ¼ 0.50) on NR2A protein levels. There
was no diagnosis · region interaction for NR1 (F ¼ 2.93;
d.f. ¼ 1,46; p ¼ 0.09) or NR2A (F ¼ 1.20; d.f. ¼ 1,46;
p ¼ 0.28). None of the NMDA receptor subunit protein






































































Fig. 2 NMDA receptor subunit expression in the dorsomedial and
ventral thalamus in schizophrenia. (a) Representative immunoblots for
NMDA receptor subunits NR2B, NR2A and NR1 using dorsomedial and
ventral thalamus samples from a patient with schizophrenia (scz) and a
control subject (con). Lanes show side-by-side duplicates of each
subject. (b) There was no main effect of diagnosis for NR2B protein
levels (upper panel), but there was a significant diagnosis · thalamic
sub–region interaction (F ¼ 6.71; d.f. ¼ 1,46; p < 0.05). Post-hoc
analysis revealed significantly increased levels of NR2B protein in the
dorsomedial thalamus of subjects with schizophrenia compared with
control subjects (**p < 0.05), but were unchanged in the ventral thala-
mus. NR2A (middle panel) and NR1 (lower panel) protein expression
was not significantly different between diagnostic groups in either tha-
lamic sub-region. Data are expressed as a ratio of the optical density
value for the protein of interest over the optical density band for b-tubulin
from the same patient.
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NMDA receptor-associated post-synaptic protein
expression in the thalamus in schizophrenia
Antibodies directed against post-synaptic density proteins
SAP102, PSD95 and NF-L all detected single prominent
bands at the appropriate molecular weights (102 kDa for
SAP102, 95 kDa for PSD95 and 68 kDa for NF-L; Fig. 3a).
There was no main effect of diagnosis (F ¼ 0.91; d.f. ¼
1,46; p ¼ 0.35) or region (F ¼ 0.34; d.f. ¼ 1,46; p ¼ 0.56)
for PSD95 protein levels, but there was a significant
diagnosis · thalamic sub-region interaction (F ¼ 5.61;
d.f. ¼ 1,46; p < 0.05; Fig. 3b). Post-hoc analysis revealed
that PSD95 protein expression was increased in the dorso-
medial thalamus of patients with schizophrenia compared
with control subjects (p < 0.05; Fisher’s PLSD), but was
unchanged in the ventral thalamus (Fig. 3b). NF-L and
SAP102 protein levels were not different between diagnostic
groups. There was no main effect of diagnosis (F ¼ 1.09;
d.f. ¼ 1,46; p ¼ 0.30) or region (F ¼ 0.44; d.f. ¼ 1,46;
p ¼ 0.51) on NF-L protein levels. There was no main effect
of diagnosis (F ¼ 1.36; d.f. ¼ 1,46; p ¼ 0.25) on SAP102
protein levels, but there was a main effect of thalamic sub-
region on SAP102 levels (F ¼ 7.31; d.f. ¼ 1,46; p < 0.05).
Post-hoc analysis revealed that SAP102 protein expression
was greater in ventral thalamus compared with dorsomedial
thalamus (Fig. 3b). There was no diagnosis · region inter-
action for NF-L (F ¼ 2.32; d.f. ¼ 1,46; p ¼ 0.13) or
SAP102 (F ¼ 0.41; d.f. ¼ 1,46; p ¼ 0.52). PSD95, NF-L
and SAP102 protein levels did not correlate with age, tissue
pH or post-mortem interval.
Discussion
While there are numerous reports of structural and functional
abnormalities of the thalamus in schizophrenia, surprisingly
few studies have examined potential neurochemical abnor-
malities that may accompany these pathological changes
(Clinton and Meador-Woodruff 2004a). Our recent work has
revealed gross disturbances of multiple molecules involved
in glutamate neurotransmission, including changes in
NMDA receptor subunit transcripts and binding sites (Ibra-
him et al. 2000), receptor-associated PSD protein transcripts
(Clinton et al. 2003), and transcripts encoding pre-synaptic
and glial-associated glutamate transporters (Smith et al.
2001a,b) in the thalamus of elderly patients with schizo-
phrenia. In the present study, we performed western blot
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Fig. 3 Post-synaptic density protein expression in the dorsomedial and
ventral thalamus in schizophrenia. (a) Representative immunoblots for
NMDA receptor-associated post-synaptic proteins SAP102, PSD95
and NF-L using dorsomedial and ventral thalamus samples from a pa-
tient with schizophrenia (scz) and a control subject (con). Lanes show
side-by-side duplicates of each subject. (b) There was no main effect of
diagnosis for PSD95 protein levels (middle panel), but there was a
significant diagnosis · thalamic sub–region interaction (F ¼ 5.61;
d.f. ¼ 1,46; p < 0.05). Post-hoc analysis revealed that PSD95 protein
expression was increased in the dorsomedial thalamus of patients with
schizophrenia compared with control subjects (*p < 0.05), but was
unchanged in the ventral thalamus. NF-L (lower panel) and SAP102
(upper panel) protein levels were not different between diagnostic
groups. There was a main effect of thalamic sub-region for SAP102
levels (F ¼ 7.31; d.f. ¼ 1,46; p < 0.05), with post-hoc analysis reveal-
ing that SAP102 protein expression was greater in ventral thalamus
compared with dorsomedial thalamus. Data are expressed as a ratio of
the optical density value for the protein of interest over the optical
density band for b-tubulin from the same patient.
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NR2B NMDA receptor subunit and its associated intracel-
lular protein, PSD95, in the dorsomedial thalamus of patients
with schizophrenia compared with control subjects. While
the pattern of protein expression changes does not entirely
correspond to our previously reported transcript and binding
data, these findings provide additional evidence of altered
glutamate neurotransmission in the thalamus in schizophre-
nia, and may reflect a complicated array of intracellular
disturbances that contribute to thalamic dysfunction in
schizophrenia.
NMDA receptor abnormalities in the thalamus in
schizophrenia
Our previous work showed reduced expression of NR1 and
NR2C NMDA receptor subunit transcripts in the thalamus in
schizophrenia (Ibrahim et al. 2000). Receptor autoradiogra-
phy studies revealed reduced expression of the glycine
binding site (located on the NR1 subunit) and polyamine
binding site (located on the NR2B subunit), although
other binding sites, including the intrachannel phencyclidine
(PCP) binding site, were unchanged (Ibrahim et al. 2000).
These data suggest that while the total number of NMDA
receptors expressed at the cell surface is unchanged in
schizophrenia, there may be a shift in subunit stoichiometry
such that there are fewer NR1 and NR2B subunits incorpor-
ated into thalamic NMDA receptor channels (Ibrahim et al.
2000). Our present western blot results show increased NR2B
NMDA receptor subunit protein in the dorsomedial thalamus
of patients with schizophrenia relative to comparison subjects
(Fig. 2b). One possible explanation for the reduction of
receptor binding together with apparently increased amounts
of NR2B protein could be that a mutation in either the NR1 or
NR2B genes in schizophrenia produces abnormal proteins.
Several studies have investigated possible genetic mutations
of NMDA receptor subunits but, by and large, these studies
have been unable to find strong associations between NMDA
receptor subunit alterations and schizophrenia (Harrison and
Weinberger 2005). Thus, this does not readily explain our
discordant protein and binding data.
An alternative explanation for the apparent discrepancy
between binding and protein data is that increased NR2B
protein is produced in the dorsomedial thalamus but is not
successfully incorporated into receptors, which are delivered
and inserted into the synaptic membrane. There is a
multitude of intracellular mechanisms that appear to regulate
the assembly of NMDA receptor subunits into functional
channels, endoplasmic reticulum retention or release of those
receptors, receptor trafficking within the cell and eventual
synaptic delivery (McIlhinney et al. 1998; Setou et al. 2000;
Standley et al. 2000; Steigerwald et al. 2000; Scott et al.
2001; Barria and Malinow 2002; Carroll and Zukin 2002;
Fukaya et al. 2003; Guillaud et al. 2003; Sans et al. 2003;
Washbourne et al. 2004). The present western data suggest
that while there are high levels of NR2B protein available,
there may be problems with NMDA receptor assembly,
endoplasmic reticulum release and/or trafficking that prevent
NR2B-containing receptors from successfully reaching the
synaptic membrane. Animal work using a selective knockout
of the NR1 gene provides in vivo evidence demonstrating
that disrupting NMDA receptor subunit composition impairs
normal subcellular targeting of NMDA channels (Fukaya
et al. 2003). Fukaya and co-workers demonstrated that NR1
gene deletion in the CA1 region of the hippocampus leads to
a reduction of NR2B protein expressed in the dendrites, and
an accumulation of NR2B subunit protein in the perikarya
where it is condensed in the lumen of the endoplasmic
reticulum (Fukaya et al. 2003). Based on our present
findings, we hope to pursue studies which will examine the
subcellular compartmentalization of NMDA receptor sub-
units in schizophrenia in order to determine whether certain
subunits (e.g. NR2B subunits) are abnormally concentrated
in the endoplasmic reticulum, rather than incorporated in
receptors expressed at the synaptic membrane. This line of
investigation would offer an intriguing new perspective on
dysregulated NMDA receptor functioning in schizophrenia.
Altered PSD95 protein expression in the thalamus in
schizophrenia
Previous in situ hybridization studies revealed increased
expression of PSD95, NF-L and SAP102 transcripts in the
thalamus in schizophrenia (Clinton et al. 2003). Results from
our current western blot studies show increased PSD95
protein expression in the dorsomedial thalamus in schizo-
phrenia, but no changes in NF-L and SAP102 protein levels
(Fig. 3b). PSD95 and other NMDA receptor-associated PSD
proteins generally promote NMDA receptor function in a
variety of ways, including participating in subcellular
targeting and trafficking of receptors to the post-synaptic
membrane (Standley et al. 2000; Scott et al. 2001; Sans
et al. 2003), modulating NMDA receptor sensitivity to
glutamate (Rutter and Stephenson 2000) and linking the
receptor to various downstream intracellular signaling path-
ways (Sheng and Pak 2000; Sheng 2001) (Fig. 4). Our
transcript, binding and western data all point to dysregulated
NMDA receptor function in the thalamus in schizophrenia.
As PSD95 generally acts to promote NMDA receptor
function, and NMDA receptor activity has been shown to
modulate PSD95 expression (Linden et al. 2001; Wyneken
et al. 2001), thalamic NMDA receptor dysfunction in
schizophrenia could conceivably stimulate a compensatory
up-regulation of PSD95 transcript and protein expression.
Although our previous transcript data revealed increased
NF-L and SAP102 mRNA levels in the thalamus of patients
with schizophrenia (Clinton et al. 2003), our present western
blot studies showed no difference in either NF-L or SAP102
protein expression in dorsomedial or ventral thalamus
(Fig. 3b). NF-L has been shown to interact with the NR1
NMDA receptor subunit (Ehlers et al. 1998) and SAP102
1120 S. M. Clinton et al.
Journal Compilation  2006 International Society for Neurochemistry, J. Neurochem. (2006) 98, 1114–1125
 2006 The Authors
interacts with the NR2 subunits (Lau et al. 1996; Muller
et al. 1996; Sans et al. 2003). Thus, it is possible that
NMDA receptor dysfunction in the thalamus stimulates a
compensatory increase in transcript expression, as it does for
PSD95. Unlike PSD95, however, the increased amounts of
NF-L and SAP102 transcripts do not appear to be translated
into increased amounts of protein.
One possible explanation for the failure to find parallel
changes in protein and mRNA is that there might be a
dissociation between the cellular localization of transcript
and protein. Transcripts are exclusively expressed in the cell
body, while protein is expressed in the soma, axons and
dendrites. Approximately 30–40% of cells in the dorsal
thalamus are inhibitory interneurons which reside wholly in
the thalamus, and the remaining 60–70% of thalamic cells
consists of large glutamatergic relay neurons which send
long projections to, and receive reciprocal input from,
cortical and subcortical structures (Steriade et al. 1997).
NMDA receptor subunit transcripts are predominantly
expressed by relay neurons (Jones 1998), and our cell-level
transcript studies suggest that PSD protein transcripts are also
concentrated in relay neurons (Clinton et al. 2003). While a
large percentage of translated NF-L and SAP102 protein may
remain in the cell body and/or dendrites of thalamic relay
cells, some of it may be transported distally to axonal sites
outside the thalamus and thus, it would not be contained in
our dissection of the dorsomedial thalamus. Furthermore, our
dissected tissue would not only include relay cell soma and
dendrites and entire inhibitory interneurons, but also afferent
fibers and terminals coming into the thalamus from else-
where in the brain. If cells projecting into the thalamus
produced and expressed abnormal amounts of PSD protein in
these distal fibers, it could contribute to this discrepancy
between observed mRNA and protein levels.
Another possibility to consider is that even with normal
(e.g. NF-L and SAP102) or elevated (e.g. PSD95) amounts
of total protein available, these post-synaptic proteins may
not properly interact with NMDA receptors, which would
further contribute to NMDA receptor dysfunction in schizo-
phrenia. Co-immunoprecipitation studies might be useful to
pursue the idea that abnormalities of the NMDA receptor
signaling complex in schizophrenia may involve a perturba-
tion of protein–protein interactions between NMDA receptor
subunits and their associated post-synaptic density proteins.
Limbic regions of thalamus appear to be most affected in
schizophrenia
Our present western blot results show increased protein
expression for the NR2B NMDA receptor subunit and its
associated post-synaptic density protein, PSD95, in the
dorsomedial, but not ventral, region of the thalamus.






























Fig. 4 Schematic diagram of a NMDA
receptor subunits interacting with post-syn-
aptic density proteins. NMDA receptor
subunits have long C-terminal intracellular
tails that bind to post-synaptic proteins like
PSD95, SAP102 and NF-L, which promote
NMDA receptor function, in part, by linking
receptors to the cytoskeleton and to specific
signal transduction molecules such as
neuronal nitric oxide synthase (nNOS),
protein phosphatase 1 (PP1), and guany-
late kinase-associated protein (GKAP).
PSD proteins also appear to participate in
sub-cellular trafficking receptors and help to
stabilize them in the synaptic membrane
after they are inserted. AMPA and meta-
botropic glutamate receptors (mGluRs)
interact with similar families of molecules,
including the AMPA receptor-associated
PICK1 and GRIP1 proteins, and Homer,
which interacts with mGluRs.
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for each patient and comparison subject. The dorsomedial
dissected region contained portions of the dorsomedial
nucleus, anterior nucleus and central medial nucleus of the
thalamus, while the ventral region contained portions of the
ventral anterior and ventral lateral nuclei of the thalamus.
Both magnetic resonance imaging studies and post-mortem
morphometric studies have reported nuclei-specific abnor-
malities in schizophrenia, including decreased volume and
cell number in the dorsomedial nucleus (Pakkenberg 1990,
1992, 1993; Popken et al. 2000; Young et al. 2000; Byne
et al. 2001; Gilbert et al. 2001; Byne et al. 2002; Danos
et al. 2003), anterior thalamic nucleus (Danos et al. 1998;
Young et al. 2000) and central medial nucleus (Gilbert et al.
2001). Furthermore, our earlier in situ hybridization and
receptor autoradiography studies showed the most prominent
NMDA receptor abnormalities to be in the dorsomedial and
central medial nuclei, both of which reciprocally project to
the prefrontal cortex and other limbic structures (Ibrahim
et al. 2000). Therefore, it is perhaps not surprising that our
most robust protein changes also occur in these limbic-
associated nuclei, rather than the non-limbic-associated
ventral tier nuclei.
Limitations of this study
Several limitations need to be considered when interpreting
data from these studies. First, an important limitation of this
and all post-mortem studies in schizophrenia is the possible
confounding effect of anti-psychotic medications, as these
drugs potentially regulate the neurochemical systems under
study. All the patients with schizophrenia used in this study
were exposed to anti-psychotic medication for decades, and it
is therefore possible that our results are related to anti-
psychotic exposure rather than being associated with the
disease process itself. While studies in both human and rat
brain have shown that anti-psychotic medications modulate
thalamic activity (Deutch et al. 1995; Cohen and Wan 1996;
Holcomb et al. 1996; Cohen and Yurgelun-Todd 2001),
rodent studies suggest that typical anti-psychotics do not
affect the expression of transcripts encoding NMDA receptor
subunits and associated PSD molecules (unpublished obser-
vations), or thalamic NMDA receptor protein expression
(Ulas et al. 1993). The present study is also limited by the
small sample size used. Finally, these data are from elderly
subjects so, while the resulting data represent thalamic
neurochemical changes that exist in the late stages of
schizophrenia, they may not generalize to younger patients.
In fact, other work in our laboratory has shown that, at least
at the level of transcript expression, middle-aged and elderly
patients with schizophrenia show divergent patterns of
glutamatergic molecular abnormalities in the thalamus,
suggesting that different stages of the disease are associated
with different neurochemical changes (Clinton and Meador-
Woodruff 2004b). Therefore, although these findings are
intriguing, it is as yet unclear whether they are primarily due
to schizophrenia or are a by-product of having this chronic
illness for many decades.
Conclusions
Several lines of evidence support a hypothesis of gluta-
matergic dysfunction in schizophrenia, including our
reports of altered NMDA receptor subunit and PSD protein
transcript expression in the thalamus (Ibrahim et al. 2000;
Clinton et al. 2003). The present western blot studies
reveal increased expression of the NR2B NMDA receptor
subunit and its associated post-synaptic density protein,
PSD95, in the dorsomedial thalamus of patients with
schizophrenia, providing further evidence of NMDA
receptor abnormalities in schizophrenia. More importantly,
however, these data suggest that glutamatergic abnormal-
ities in the illness may involve myriad intracellular
changes, which may include altered sub-cellular trafficking
of the NMDA receptor, or a breakdown of glutamate
receptor signaling pathways due to insufficient linkage
between NMDA receptors and their associated PSD
proteins. PSD95-like molecules, which exist for several
other neurotransmitter receptor families besides glutamate
receptors (see Lezcano et al. 2000; Lidow et al. 2001; Koh
et al. 2003; Clinton et al. 2005), provide a substrate for
cross-talk between different neurotransmitter systems (e.g.
glutamate and dopamine); thus, abnormalities of PSD95
and other key intracellular molecules may be crucial
to understanding molecular neurobiological mechanisms
involved in schizophrenia.
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